cheppu nerunjil ennai for the management of childhood asthma in children.

clinical evaluation of cheppu nerunjil ennai for the management of sooli kanam(childhood asthma) in children.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/08/027154

Enrollment

Registered

2020-08-14

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J459- Other and unspecified asthma

Interventions

Intervention1: cheppu nerunjil ennai (internal): cheppu nerunjil ennai (internal) dose- 5ml(BD) DURATION-7 DAYS Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: frequent Cough Tightness of chest Shortness of breath Abdominal bloating Loss of appetite

Exclusion criteria

Exclusion criteria: status asmaticus Pneumonia congenital heart disease Any other serious illness

Design outcomes

Primary

Measure	Time frame
Efficacy of the trial drug is measured by paediatric asthma severity score.Timepoint: 1 year	—

Secondary

Measure	Time frame
Improvement in clinical symptoms by peak expiratory flow meter.. Timepoint: 18 months	—

Countries

India

Contacts

Public ContactDr M Meenakshi sundaram

National institute of Siddha

mmssiddha@gmail.com9444214582

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026